http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 09:25:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Hold+Rating+on+BioMarin+Pharmaceutical+Inc.+%28BMRN%29/26670965.html <p>Stifel analyst Paul Matteis reiterated a Hold rating and $68.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).</p><p>The analyst commented, "At our West Coast Bus Tour, we caught up with BMRN CEO Alexander Hardy and EVP, R&D Greg Fiberg. Key takeaways include: (1) a seemingly bullish updated outlook on revenue targets for Galafold/PomOp and cost synergies from FOLD acquisition are expected with 2Q update, (2) BMRN can leverage their capabilities/expertise to drive penetration for these products in various RoW markets, (3) they plan to invest cash flows from new commercial products into R&D, where they have capacity for multiple early-stage http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Hold+Rating+on+BioMarin+Pharmaceutical+Inc.+%28BMRN%29/26670965.html Mon, 22 Jun 2026 09:25:18 -0400 BMRN http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Neutral+Rating+on+BioMarin+Pharmaceutical+Inc.+%28BMRN%29/26669652.html <p>H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $50.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).</p><p>The analyst commented: "New data from a Phase 2, investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia (HCH), led by Andrew Dauber, M.D. and investigators at Children's National Hospital, demonstrated sustained improvements in annualized growth velocity (AGV) and height standard deviation score (SDS). Mean height SDS improved by 0.72 SD over three years of treatment, while mean AGV increased from 4.27cm/year at baseline to 7.24cm/year at year one (p<0.001) and remained above baseline through years two and three. Last http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Neutral+Rating+on+BioMarin+Pharmaceutical+Inc.+%28BMRN%29/26669652.html Mon, 22 Jun 2026 06:58:07 -0400 BMRN http://www.streetinsider.com/Corporate+News/BioMarin+shares+VOXZOGO+three-year+data+and+BMN+333+Phase+1+results/26651665.html <p>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new clinical data on VOXZOGO (vosoritide) in hypochondroplasia and its investigational drug BMN 333 in achondroplasia at ENDO 2026, the Endocrine Society Annual Meeting in Chicago, according to a company press release.</p><p>A Phase 2, investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia, led by Andrew Dauber, M.D. at Children's National Hospital, showed mean height standard deviation score improved by 0.72 SD over three years. Mean annualized growth velocity increased from 4.27 cm/year at baseline to 7.24 cm/year at year one and remained above baseline through years two and three. No significant http://www.streetinsider.com/Corporate+News/BioMarin+shares+VOXZOGO+three-year+data+and+BMN+333+Phase+1+results/26651665.html Tue, 16 Jun 2026 09:05:38 -0400 BMRN http://www.streetinsider.com/FDA/BioMarin+shares+VOXZOGO+three-year+data+and+BMN+333+Phase+1+results/26651665.html <p>BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new clinical data on VOXZOGO (vosoritide) in hypochondroplasia and its investigational drug BMN 333 in achondroplasia at ENDO 2026, the Endocrine Society Annual Meeting in Chicago, according to a company press release.</p><p>A Phase 2, investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia, led by Andrew Dauber, M.D. at Children's National Hospital, showed mean height standard deviation score improved by 0.72 SD over three years. Mean annualized growth velocity increased from 4.27 cm/year at baseline to 7.24 cm/year at year one and remained above baseline through years two and three. No significant http://www.streetinsider.com/FDA/BioMarin+shares+VOXZOGO+three-year+data+and+BMN+333+Phase+1+results/26651665.html Tue, 16 Jun 2026 09:05:38 -0400 BMRN http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/Press+Releases/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html <div class="xn-content"> <p class="prntac"><i>Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia</i></p><p class="prntac"><i>New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanael" idsrc="xmltag.org" >SAN RAFAEL, Calif.</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BMRN" idsrc="xmltag.org" >BioMarin Pharmaceutical Inc.</span> (Nasdaq: BMRN) announced new data from studies of VOXZOGO^® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the <span>Endocrine Society</span> Annual Meeting, in <location value="LU/us.il.chicgo" idsrc="xmltag.org" >Chicago</location>.</p> <div http://www.streetinsider.com/PRNewswire/BioMarin+Announces+New+Three-Year+VOXZOGO%C2%AE+%28vosoritide%29+Data+in+Hypochondroplasia+and+BMN+333+Early+Results+at+ENDO+2026/26651659.html Tue, 16 Jun 2026 09:05:00 -0400 A.06822034 A.25838468 A.31066700 BMRN O.00004461 O.12396261 O.20026344 O.22422661 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Countouriotis+Athena/26607115.html si-local-file:///var/storage/secattach/20260604/26607115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Countouriotis+Athena/26607115.html Thu, 04 Jun 2026 18:10:00 -0400 BMRN O.00004461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Countouriotis+Athena/26607115.html si-local-file:///var/storage/secattach/20260604/26607115.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Countouriotis+Athena/26607115.html Thu, 04 Jun 2026 18:10:00 -0400 BMRN O.00004461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Walbert+Timothy+P/26607111.html si-local-file:///var/storage/secattach/20260604/26607111.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Walbert+Timothy+P/26607111.html Thu, 04 Jun 2026 18:09:00 -0400 BMRN O.00004461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Walbert+Timothy+P/26607111.html si-local-file:///var/storage/secattach/20260604/26607111.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Walbert+Timothy+P/26607111.html Thu, 04 Jun 2026 18:09:00 -0400 BMRN O.00004461 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Ho+Maykin/26607109.html si-local-file:///var/storage/secattach/20260604/26607109.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BIOMARIN+PHARMACEUTICAL+++For%3A+Jun+02++Filed+by%3A+Ho+Maykin/26607109.html Thu, 04 Jun 2026 18:08:00 -0400 BMRN O.00004461